- More than 50 issued patents covering a range of biologic therapeutic and diagnostic discoveries, and also the ECTA Platform (Enzyme- catalyzed Therapeutic Agents), which are small molecules converted by overexpressed intracellular enzymes for treatment of cancer and other diseases.
Immunotherapy
- Monoclonal antibodies directed to the HER2 receptor. US5677171A.
- A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors. Covered all antibodies, including vaccine antibodies, vs. p185HER2.
TREATMENT OF TUMOR CELL BY INHIBITING FUNCTION OF GROWTH FACTOR RECEPTOR
- An antibody capable of binding to a therapeutically effective amount of an antibody capable of binding to HER2 protein, and a prescription for administering the antibody and a cytotoxic factor, a cytokine (preferably tumor necrosis factor-, etc.), or a chemotherapeutic medicine (preferably vinblastine) into a patient. The antibody preferably sensitizes tumor cells against the cytotoxic action of the cytotoxic factor, the cytokine or the chemotherapeutic medicine, and includes a monoclonal antibody resistant to HER2 protein and isolated from a continuous hybrid cell line formed by the fusion of myeloma cells to lymphocytes.
- Discovery of the link between growth factors and resistance to the innate immune system.
- Granted in Japan, but otherwise abandoned in favor of US56771A, above.
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
- Patent number: 11584923
- Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
- Date of Patent: February 21, 2023
- Adenosine is immunosuppressive and depletion can enhance immunity in a solid tumor.
METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER;
- Publication number: 20220288226
- Abstract: Provided are molecular constructs that target tumor necrosis factor receptor 1 (TNFR1) and/or tumor necrosis factor receptor 2 (TNFR2). The constructs are for treating diseases, disorders, and conditions in which these receptors and/or TNF are involved in the etiology or in which their inhibition or activation thereof can ameliorate the disease, disorder, and condition or a symptom thereof. Among the constructs provided herein, are TNFR1 antagonist constructs that are engineered to inhibit TNFR1 function, and to eliminate any TNFR1 agonist activity. The constructs provided herein include agonists and antagonists of TNFR1 and TNFR2 Included also are agonists and antagonists of TNFR2. Agonists of TNFR2 increase regulatory T-cell function to control acute or chronic inflammation. Antagonists of TNFR2 decrease regulatory T-cell function thus increasing immunity, and are for treating cancer and certain immunodeficiency diseases.
- Type: Application
- Filed: April 28, 2022
- Mab-like proteins vs. TNFR1 and TNFR2.
ANTIBODIES AND ENONOMERS
- Publication number: 20220175945
- Abstract: The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.
- Type: Application
- Filed: February 19, 2020
- Antibody scaffolds, pegylated linkers and aptamers.
Conditionally Active (prodrugs/antibodies/enzymes)
Enzyme catalyzed therapeutic compounds;
- Patent number: 7605144
- Abstract: This invention provides novel compounds selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analogs. The compounds are useful to treat or prevent diseases such as cancer.
- Type: Grant
- Date of Patent: October 20, 2009
Enzyme catalyzed therapeutic agents;
- Patent number: 6245750
- Abstract: This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or chemotherapy. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Further provided by this invention is a method for treating a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.
- Type: Grant;
- Filed: January 22, 1999
- Date of Patent: June 12, 2001
- Design of prodrugs activated by enzymes overexpressed in the diseased cell.
- Patent number: 9683985
- Abstract: Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
- Date of Patent: June 20, 2017
- This technology can be applied to antibodies and enzymes.
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
- Patent number: 9969998
- Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
- Type: Grant Filed: April 8, 2016
- Date of Patent: May 15, 2018
- Assignee: Halozyme, Inc.
- Inventors: Christopher D. Thanos, Lin Wang, H. Michael Shepard
- Patent number: 11414489
- Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
- Type: Grant
- Filed: February 27, 2017
- Date of Patent: August 16, 2022
- Assignee: Halozyme, Inc.
- Inventors: Sanna Rosengren, H. Michael Shepard, Curtis B. Thompson